## Core Concept
The question tests knowledge of antiplatelet drugs, specifically those that target the glycoprotein IIb/IIIa (GP IIb/IIIa) receptor on platelets. GP IIb/IIIa antagonists are used to prevent platelet aggregation and are crucial in the management of acute coronary syndromes and during percutaneous coronary interventions.

## Why the Correct Answer is Right
Tirofiban is a non-peptide tyrosine derivative that acts as a GP IIb/IIIa antagonist. It competes with fibrinogen for binding to the GP IIb/IIIa receptor, thereby inhibiting platelet aggregation. This mechanism is critical in the setting of acute coronary syndromes and during procedures like angioplasty.

## Why Each Wrong Option is Incorrect
* **Option A:** Abciximab is a monoclonal antibody that targets the GP IIb/IIIa receptor. It is used to prevent platelet aggregation during coronary interventions. Therefore, it is a GP IIb/IIIa antagonist.
* **Option B:** Eptifibatide is a synthetic peptide and a potent GP IIb/IIIa inhibitor. It is used in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. Thus, it is also a GP IIb/IIIa antagonist.
* **Option D:** Prasugrel is a P2Y12 receptor inhibitor, not a GP IIb/IIIa antagonist. It works by irreversibly inhibiting the P2Y12 receptor on platelets, preventing ADP-mediated platelet activation and aggregation.

## Clinical Pearl / High-Yield Fact
A key point to remember is that GP IIb/IIIa antagonists are particularly useful in the setting of acute coronary syndromes and during percutaneous coronary interventions because they provide immediate and potent inhibition of platelet aggregation. However, their use requires careful monitoring due to the risk of bleeding.

## Correct Answer: D. Prasugrel